Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune system to recognize and eliminate cancer cells before tumors develop Final...
Latest News
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation off-the-shelf and personalized neoantigen cancer immunotherapies, today announced the presentation of new clinical and translational data on its lead candidate NOUS-209 at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting. Following positive safety and immunogenicity data reported at...
FALLS CHURCH, Va. – This year, nearly 2 million Americans will be diagnosed with cancer. But one-quarter won’t fill their expensive prescriptions, and another 20% will ration their drugs due to cost – which can total $15,000 per month or more. But thanks to a partnership between NOVA ScriptsCentral and...
Mont Saint-Guibert and Brussels, Belgium – Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, and the Cliniques universitaires Saint-Luc today announce the successful treatment of four pediatric patients with Congenital Pseudarthrosis of the Tibia (CPT) using NVD003, an autologous therapy developed by Novadip for the reconstruction of...
Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert – Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s...
Mont Saint-Guibert, Belgium – Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, today announces the recruitment of the first pediatric patients for the pivotal phase 3 trial of its tissue regeneration product NVD003 in congenital pseudoarthrosis of the tibia (CPT). Phoenix Children’s Hospital, (Phoenix, AZ, USA), and...
Basel, Switzerland – Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren’s disease. Both trials met the primary endpoint of demonstrating statistically significant improvements in disease activity1. These results support the potential for ianalumab, a drug with a dual mechanism...
EAST HANOVER, N.J. – Novartis today announced important findings from a real-world study evaluating the safety and efficacy of alpelisib for people living with PIK3CA-Related Overgrowth Spectrum (PROS) who received treatment daily for at least 24 weeks. Results from EPIK-P1 showed alpelisib effectively reduced volume of clinically significant PROS-related lesions and...
Basel – Novartis today announced Phase II primary endpoint data showing investigational iptacopan (LNP023) – a first-in-class, oral, targeted factor B inhibitor – reduced protein in the urine (proteinuria), an increasingly recognized surrogate marker correlating with progression to kidney failure[2], and showed promise in stabilizing kidney function in patients with...
Basel – Novartis announced that the Novartis Vaccines Institute for Global Health (NVGH) has been awarded a grant from the Wellcome Trust to develop a bivalent vaccine for Typhoid fever, a disease that affects more than 21 million people worldwide every year. The Euro 5.15 million grant will fund preclinical...